KNKristoffer Nilsson

Kristoffer Nilsson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kristoffer Nilsson has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Validation of the IHE type 2 diabetes cohort model in the Japanese clinical setting

    by Kristoffer Nilsson, Adam Fridhammar, Riku Ota, Morten Sall Jensen, Michael Willis, Sofie Persson

    AimsEconomic simulation models, such as the IHE Type 2 Diabetes Cohort Model (IHE-DCM-T2), are used widely to inform resource allocation for Type 2 Diabetes (T2D) treatments. Recently, IHE-DCM-T2 was augmented with Japanese-specific risk equations for coronary heart disease, stroke, non-proliferative and proliferative retinopathy, macroalbuminuria, and non-CV mortality to better align with the Japanese healthcare context. This study aims to update and extend prior model validation of IHE-DCM-T2 to cover the Japanese risk equations for model applications intended for Japan's clinical setting and healthcare system.Materials and MethodsFace validity was assessed through expert review of model assumptions and structure. Model programming was verified by detailed code review and 728 stress tests designed to identify errors in logic and in programming. Predictive accuracy was tested by comparing model predictions to real-world outcomes from 28 Japanese studies, assessing concordance visually, with best-fitting regression lines, and with mean absolute percentage error (MAPE), root mean square percentage error (RMSPE), mean squared logarithmic error (MSLE), and mean squared log-absolute error (MSLAR). Subgroup analyses examined dependent and independent endpoints, along with mortality, microvascular, and macrovascular outcomes. Sensitivity analyses assessed model robustness to variations in scale and validation study sample size.ResultsIHE-DCM-T2 demonstrated face validity and correct implementation. External validation against 120 endpoints showed good alignment between predicted and observed event rates, with a regression line slope of 0.96 and an R2 of 0.98. Overall, the prediction error metrics were: MAPE = 0.83, RMSPE = 1.21, MSLE = 0.61, and MSLAR = 0.53. As expected, predictions were more accurate for dependent than independent endpoints. Among endpoint categories, macrovascular events had the lowest average errors, whereas mortality endpoints had the highest MAPE and RMSPE, and microvascular endpoints had the highest MSLE and MSLAR. Predictive accuracy was consistent across alternative test specifications.LimitationsLimitations included gaps in validation data, as studies often omit necessary information, and the requirement for long-term follow-up that inherently reflects past treatment patterns. Additionally, some gaps in the Japanese risk equations required the use of complementary non-Japanese risk equations. To ensure robustness, only studies with at least 1,000 patients were included in the validation studies, which may introduce selection bias.ConclusionsThis comprehensive validation of the IHE-DCM-T2, augmented with Japanese-specific risk equations, demonstrated its suitability for health technology assessments and resource allocation decisions for T2D in the Japanese clinical setting and healthcare system.

  • Open Access

    Atherosclerotic Cardiovascular Disease in Type 2 Diabetes: A Retrospective, Observational Study of Economic and Clinical Burden in Sweden

    by Katarina Steen Carlsson, Mads Faurby, Kristoffer Nilsson, Michael Lyng Wolden

    Introduction Individuals with type 2 diabetes (T2D) are at high risk of experiencing atherosclerotic cardiovascular disease (ASCVD), which is associated with morbidity, mortality and healthcare resource utilisation. Clinical guidelines recommend the use of glucose-lowering medications with cardiovascular benefits in individuals with T2D and cardiovascular disease, but there is evidence that this is not reflected in clinical practice. We used linked national registry data from Sweden to compare outcomes in people with T2D and ASCVD against matched controls with T2D without ASCVD, over 5 years. Direct costs (inpatient, outpatient and selected drug costs), indirect costs resulting from work absence, early retirement, cardiovascular events and mortality were examined. Methods Individuals with T2D who were at least 16 years old and were alive and resident in Sweden on 1 January 2012 were identified in an existing database. In four separate analyses, individuals with a record indicating ASCVD according to a broad definition, peripheral artery disease (PAD), stroke or myocardial infarction (MI) before 1 January 2012 were identified using diagnosis and/or procedure codes and propensity score matched 1:1 to controls with T2D and without ASCVD, using covariates for birth, sex and level of education in 2012. Follow-up continued until death, migration from Sweden or the end of the study period in 2016. Results In total, 80,305 individuals with ASCVD, 15,397 individuals with PAD, 17,539 individuals with previous stroke and 25,729 individuals with previous MI were included. Total mean annual costs per person were €14,785 for PAD (2.7 × costs for controls), €11,397 for previous stroke (2.2 × controls), €10,730 for ASCVD (1.9 × controls) and €10,342 for previous MI (1.7 × controls). Indirect costs and costs of inpatient care were the major cost drivers. ASCVD, PAD, stroke and MI were all associated with an increased likelihood of early retirement, cardiovascular events and mortality. Conclusions ASCVD is associated with considerable costs, morbidity and mortality in individuals with T2D. These results support structured assessment of ASCVD risk and broader implementation of guideline-recommended treatments in T2D healthcare.


  • Open Access

    Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease

    by Kristoffer Nilsson, Emelie Andersson, Sofie Persson, Kristina Karlsdotter, Josefin Skogsberg, Staffan Gustavsson, Johan Jendle, Katarina Steen Carlsson

    Aim: To perform a model‐based analysis of the short‐ and long‐term health benefits and costs of further increased implementation of empagliflozin for people with type 2 diabetes and established cardiovascular disease (eCVD) in Sweden. Materials and Methods: The validated Institute for Health Economics Diabetes Cohort Model (IHE‐DCM) was used to estimate health benefits and a 3‐year budget impact, and lifetime costs per quality‐adjusted life years (QALY) gained of increased implementation of adding empagliflozin to standard of care (SoC) for people with type 2 diabetes and eCVD in a Swedish setting. Scenarios with 100%/75%/50% implementation were explored. Analyses were based on 30 model cohorts with type 2 diabetes and eCVD (n = 131 412 at baseline) from national health data registers. Sensitivity analyses explored the robustness of results. Results: Over 3 years, SoC with empagliflozin (100% implementation) versus SoC before empagliflozin resulted in 7700 total life years gained and reductions in cumulative incidence of cardiovascular deaths by 30% and heart failures by 28%. Annual costs increased by 15% from higher treatment costs and increased survival. Half of these benefits and costs are not yet reached with current implementation below 50%. SoC with empagliflozin yielded 0.37 QALYs per person, with an incremental cost‐effectiveness ratio of 16 000 EUR per QALY versus SoC before empagliflozin. Conclusions: Model simulations using real‐world data and trial treatment effects indicated that a broader implementation of empagliflozin, in line with current guidelines for treatment of people with type 2 diabetes and eCVD, would lead to further benefits even from a short‐term perspective.


  • Open Access

    The implementation of a noninvasive lymph node staging (NILS) preoperative prediction model is cost effective in primary breast cancer

    by Ida Skarping, Kristoffer Nilsson, Looket Dihge, Adam Fridhammar, Mattias Ohlsson, Linnea Huss, Pär-Ola Bendahl, Katarina Steen Carlsson, Lisa Rydén

    Purpose: The need for sentinel lymph node biopsy (SLNB) in clinically node-negative (cN0) patients is currently questioned. Our objective was to investigate the cost-effectiveness of a preoperative noninvasive lymph node staging (NILS) model (an artificial neural network model) for predicting pathological nodal status in patients with cN0 breast cancer (BC). Methods: A health-economic decision-analytic model was developed to evaluate the utility of the NILS model in reducing the proportion of cN0 patients with low predicted risk undergoing SLNB. The model used information from a national registry and published studies, and three sensitivity/specificity scenarios of the NILS model were evaluated. Subgroup analysis explored the outcomes of breast-conserving surgery (BCS) or mastectomy. The results are presented as cost (€) and quality-adjusted life years (QALYs) per 1000 patients. Results: All three scenarios of the NILS model reduced total costs (–€93,244 to –€398,941 per 1000 patients). The overall health benefit allowing for the impact of SLNB complications was a net health gain (7.0–26.9 QALYs per 1000 patients). Sensitivity analyses disregarding reduced quality of life from lymphedema showed a small loss in total health benefits (0.4–4.0 QALYs per 1000 patients) because of the reduction in total life years (0.6–6.5 life years per 1000 patients) after reduced adjuvant treatment. Subgroup analyses showed greater cost reductions and QALY gains in patients undergoing BCS. Conclusion: Implementing the NILS model to identify patients with low risk for nodal metastases was associated with substantial cost reductions and likely overall health gains, especially in patients undergoing BCS.


  • Complete skin clearance and Psoriasis Area and Severity Index response rates in clinical practice: predictors, health‐related quality of life improvements and implications for treatment goals

    by J.M. Norlin, K. Nilsson, U. Persson, M. Schmitt‐Egenolf

    Background Psoriasis Area and Severity Index (PASI) 90 is suggested to be the new standard endpoint for randomized controlled trials of biologics for psoriasis, whereas treatment guidelines often still refer to PASI 75. Objectives To analyse in a real-world setting: firstly, what factors are associated with higher levels of treatment response to biologics; secondly, the health-related quality of life gains associated with different response levels in clinical practice. Methods Biologically naïve patients with PASI, Dermatology Life Quality Index (DLQI) and EuroQol (EQ)-5D outcomes before (maximum 6 months) and after (3–12 months) switch to biologics during registration in the Swedish National Registry for Systemic Treatment of Psoriasis (PsoReg) were included (n = 515). Patient characteristics associated with higher treatment response were analysed by regression analyses. Improvements in absolute PASI, DLQI and EQ-5D were assessed in different PASI percentage response levels. Results High PASI percentage response was associated with higher PASI before switch and lower body mass index. DLQI and EQ-5D improved within all responder groups (P < 0·001). The magnitude of improvements in DLQI (P = 0·02) differed between responder groups. The mean (SD) DLQI improvements for PASI 7530 achieved complete skin clearance (CSC). All responder groups achieved significant HRQoL improvements. Patients achieving CSC (PASI 100) had lower absolute PASI before switch and lower improvements in absolute PASI and HRQoL than patients with almost cleared skin. What are the clinical implications of this work? Relative measures based on PASI percentage, such as PASI 75 or PASI 90, are not suitable for treatment guidelines or for follow-up in clinical practice.